Abstract 2954
Background
RM-1929 photoimmunotherapy (PIT) consists of the EGFR-directed antibody cetuximab conjugated to a dye (IRDye® 700DX). Binding of the antibody-dye conjugate to cancer cells followed by photoactivation with non-thermal red light induces selective and rapid tumour cell death.
Methods
An integrated analysis of safety, PK, and immunogenicity was conducted in subjects with rHNSCC who received RM-1929 PIT in Phase 1 and Phase 1/2a trials.
Results
Forty-one subjects were treated with RM-1929 PIT. There were no dose-limiting toxicities or clinically significant shifts in chemistry, hematology, or ECGs. The observed TEAEs by grade were: Grade 1 – 97.6% (40/41); Grade 2 – 85.4% (35/41); Grade 3 – 58.5% (24/41); Grade 4 – 12.2% (5/41); and Grade 5 – 7.3% (3/41). The most frequent TEAEs (>15% incidence) included fatigue, application site pain, dysphagia, constipation, cough, erythema, and face edema. Three photosensitivity reactions were observed. All Grade 4 TEAEs (anemia, myocardial infarction, sepsis, hypoglycemia, tumor hemorrhage, obstructive airway and pneumothorax) resolved. 41.5% (17/41) of subjects experienced SAEs, while 12.2% (5/41) were considered treatment related SAEs (oral pain, tumor pain, obstructive airways disorder, and tumor hemorrhage-non fatal). Three subjects experienced SAEs that led to death (pneumonia, tumor hemorrhage, and arterial hemorrhage) that were considered unrelated to treatment due to the late onset of the events. PK analysis showed that RM-1929 exposure (AUC) increased with escalating doses in a dose proportional manner. At 640 mg/m2 RM-1929 dose, AUC reaches a range expected to achieve full saturation of EGFR binding in tissues when compared to a single 250 mg/m2 dose of Erbitux. In subsequent cycles, the mean CL, Vss and T1/2 estimates appeared comparable to those in Cycle 1. Immunogenicity (anti-drug antibody) was detected in 9.5% (4/42) of subjects, 3 of which emerged post-treatment.
Conclusions
The integrated clinical safety data indicated that RM-1929 PIT treatment had a favorable safety profile with no unexpected safety concerns.
Clinical trial identification
NCT02422979.
Editorial acknowledgement
Legal entity responsible for the study
Rakuten Medical, Inc.
Funding
Rakuten Medical, Inc.
Disclosure
J.M. Johnson: Advisory / Consultancy: Foundation Medicine; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck; Research grant / Funding (institution): AstraZeneca. J.M. Curry: Research grant / Funding (institution): AstraZeneca. S.T. Kochuparambil: Shareholder / Stockholder / Stock options, Full / Part-time employment: Minnesota Hematology Oncology; Advisory / Consultancy: BMS. D.R. McDonald: Travel / Accommodation / Expenses, Formerly Rakuten Aspyrian: Rakuten Medical, Inc. M.J. Fidler: Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Guardant Health; Honoraria (self), Advisory / Consultancy: AstraZeneca; Speaker Bureau / Expert testimony: Merck; Research grant / Funding (self): Biodesix. N.R. Vasan: Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Licensing / Royalties: Adroit Surgical, LLC. M.A. Razaq: Shareholder / Stockholder / Stock options: AbbVie; Honoraria (self), Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, previously Rakuten Aspyrian: Rakuten Medical. M. Tahara: Honoraria (self): Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): BMS; Honoraria (self): Eisai; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (self): MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy, (previously Rakuten Aspyrian): Rakuten Medical; Research grant / Funding (self): Loxo; Research grant / Funding (self): Novartis. M.A. Biel: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. M. Tello: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. M. Garcia-Guzman: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. E. Sun: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. A.M. Gillenwater: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Masimo; Advisory / Consultancy: Novartis; Travel / Accommodation / Expenses, Previously Rakuten Aspyrian: Rakuten Medical, Inc.; Travel / Accommodation / Expenses: IAOO Conference. All other authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract